Cellectar Biosciences, Inc. (Nasdaq: CLRB) announces positive data from the second cohort of patients enrolled in its orphan-drug designated Phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE